ArticleVeterinary research2021
Chimeric HP-PRRSV2 containing an ORF2-6 consensus sequence induces antibodies with broadly neutralizing activity and confers cross protection against virulent NADC30-like isolate.
Article in Veterinary research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Pathogenicity and virulence of PRRSV: From regulated cell death reprogramming landscape and immune subversion to precision vaccinology.Virulence · 2026Review
- Unraveling the complexity of PRRSV-2 recombination: recombination frequency, replication efficiency, and backbone fitness define highly recombinogenic backbone and evolutionary bottlenecks.Microbiology spectrum · 2026Article
- Cross-Protection in PRRSV: Mechanisms, Limitations, and Implications for Vaccine Design.Pathogens (Basel, Switzerland) · 2026Review
- Article
- A centralised immunogen approach to develop a more broadly protective modified live porcine reproductive and respiratory syndrome virus 1 vaccine candidate.NPJ vaccines · 2025Article
- The GP2a 91/97/98 amino acid substitutions play critical roles in determining PRRSV tropism and infectivity but do not affect immune responses.Journal of virology · 2025Article
- Isolation and Genomic Characterization of a Novel Porcine Reproductive and Respiratory Syndrome Virus 1 from Severely Diseased Piglets in China in 2024.Veterinary sciences · 2025Article
- Ten years after introduction of NADC30-like strain in China: a novel chimeric porcine reproductive and respiratory syndrome vaccine candidate.Frontiers in immunology · 2025Article
- Epidemiology and Pathogenicity Analysis Based on Partial Recombinant PRRSV Strains in China.Transboundary and emerging diseases · 2025Article
- The role of major and minor structural proteins of porcine reproductive and respiratory syndrome virus in induction of protective immunity.Frontiers in microbiology · 2025Article
- Genetic and Pathogenic Characteristics of an Emerging Lineage 7 PRRSV-2 (Prime Pac-Like) Strain in China.Transboundary and emerging diseases · 2025Article
- A chimeric strain of porcine reproductive and respiratory syndrome virus 2 derived from HP-PRRSV and NADC30-like PRRSV confers cross-protection against both strains.Veterinary research · 2024Article
- Parallel single B cell transcriptomics to elucidate pig B cell repertoire.Scientific reports · 2024Article
- A chimeric porcine reproductive and respiratory syndrome virus 1 strain containing synthetic ORF2-6 genes can trigger T follicular helper cell and heterologous neutralizing antibody responses and confer enhanced cross-protection.Veterinary research · 2024Article
- Propidium Monoazide Integrated With qPCR Enables Rapid and Universal Detection of Infectious Porcine Reproductive and Respiratory Syndrome Viruses.Transboundary and emerging diseases · 2024Article
- Genomic similarity and antibody-dependent enhancement of immune serum potentially affect the protective efficacy of commercial MLV vaccines against NADC30-like PRRSV.Virologica Sinica · 2023Article
- Genomic Characterizations of Porcine Epidemic Diarrhea Viruses (PEDV) in Diarrheic Piglets and Clinically Healthy Adult Pigs from 2019 to 2022 in China.Animals : an open access journal from MDPI · 2023Article
- Research Progress on Glycoprotein 5 of Porcine Reproductive and Respiratory Syndrome Virus.Animals : an open access journal from MDPI · 2023Review
- Metagenomic and Pathogenic Assessments Identify a Pathogenic Porcine Reproductive and Respiratory Syndrome Virus 1 with New Deletions from Adult Slaughter Pig in 2022.Transboundary and emerging diseases · 2023Article
- CD163-Expressing Porcine Macrophages Support NADC30-like and NADC34-like PRRSV Infections.Viruses · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
Abstract
Due to the substantial genetic diversity of porcine reproductive and respiratory syndrome virus (PRRSV), commercial PRRS vaccines fail to provide sufficient cross protection. Previous studies have confirmed the existence of PRRSV broadly neutralizing antibodies (bnAbs). However, bnAbs are rarely induced by either natural infection or vaccination. In this study, we designed and synthesized a consensus sequence of PRRSV2 ORF2-6 genes (ORF2-6-CON) encoding all envelope proteins based on 30 representative Chinese PRRSV isolates. The ORF2-6-CON sequence shared > 90% nucleotide identities to all four lineages of PRRSV2 isolates in China. A chimeric virus (rJS-ORF2-6-CON) containing the ORF2-6-CON was generated using the avirulent HP-PRRSV2 JSTZ1712-12 infectious clone as a backbone. The rJS-ORF2-6-CON has similar replication efficiency as the backbone virus in vitro. Furthermore, pig inoculation and challenge studies showed that rJS-ORF2-6-CON is not pathogenic to piglets and confers better cross protection against the virulent NADC30-like isolate than a commercial HP-PRRS modified live virus (MLV) vaccine. Noticeably, the rJS-ORF2-6-CON strain could induce bnAbs while the MLV strain only induced homologous nAbs. In addition, the lineages of VDJ repertoires potentially associated with distinct nAbs were also characterized. Overall, our results demonstrate that rJS-ORF2-6-CON is a promising candidate for the development of a PRRS genetic engineered vaccine conferring cross protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.